Feature
New Collaboration to Automate Cell Therapy Manufacturing with Robotics
-
By
February 12, 2026
-
2 min
-
1
Multiply Labs partners with AstraZeneca.
-
2
Focus on end-to-end robotic automation for cell therapy.
-
3
Aim for scalable manufacturing while ensuring quality.
-
4
Robotic systems utilize four parallel arms.
-
5
Enhanced efficiency targets higher productivity in existing facilities.
-
Multiply Labs has partnered with AstraZeneca to explore the integration of robotic systems into commercial-scale cell therapy manufacturing. The collaboration aims to enhance the efficiency and scalability of cell therapy production while adhering to stringent quality and regulatory standards. Fred Parietti, CEO of Multiply Labs, emphasizes the promise of cell therapies and the need to improve manufacturing processes. Their advanced robotic systems utilize multiple arms to streamline existing practices and increase productivity in the industry.
-
1
Multiply Labs partners with AstraZeneca.
-
2
Focus on end-to-end robotic automation for cell therapy.
-
3
Aim for scalable manufacturing while ensuring quality.
-
4
Robotic systems utilize four parallel arms.
-
5
Enhanced efficiency targets higher productivity in existing facilities.
Listen Tab content
